Multiple sclerosis (MS) is associated with changes in the metabolome. Numerous studies employing varying metabolomics platforms have examined a range of biological material ranging from brain tissue to urine and demonstrated consistently alterations in multiple metabolic pathways in MS. We review not only the studies that describe the ability of metabolomics to differentiate MS patients from healthy controls and other neurological disease but also discuss the potential of metabolomics-based methods to build predictive models that are able to stage disease, monitor progression, and select the most appropriate therapy. The increasing number of impressive claims for the capacity of metabolomics to distinguish between different types of demyelinating disease suggests that the provision of such tests may be close at hand. Besides the ability to provide potential diagnostic and prognostic biomarkers, metabolomics also provides us with unique insights into the pathophysiology of the disease and helps identify metabolic pathways that may be potential therapeutic targets. Future studies will integrate metabolomics data with other omics techniques to provide further insight into the source of these metabolic abnormalities and help with identification of the most promising targets for therapeutic intervention.
ReichDSLucchinettiCFCalabresiPA. Multiple Sclerosis. N Engl J Med2018; 378(2): 169–180.
2.
ThompsonAJBanwellBLBarkhofF, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol2018; 17(2): 162–173.
3.
BhargavaPCalabresiPA. Metabolomics in multiple sclerosis. Mult Scler2016; 22(4): 451–460.
4.
MungerKLBentzenJLaursenB, et al. Childhood body mass index and multiple sclerosis risk: A long-term cohort study. Mult Scler2013; 19(10): 1323–1329.
5.
AscherioAMungerKLWhiteR, et al. Vitamin D as an early predictor of multiple sclerosis activity and progression. JAMA Neurol2014; 71: 306–314.
6.
JangiSGandhiRCoxLM, et al. Alterations of the human gut microbiome in multiple sclerosis. Nat Commun2016; 7: 12015.
7.
CantarelBLWaubantEChehoudC, et al. Gut microbiota in multiple sclerosis: Possible influence of immunomodulators. J Investig Med2015; 63(5): 729–734.
8.
KornbergMDBhargavaPKimPM, et al. Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity. Science2018; 360: 449–453.
9.
NeighGNBilboSDHotchkissAK, et al. Exogenous pyruvate prevents stress-evoked suppression of mitogen-stimulated proliferation. Brain Behav Immun2004; 18(5): 425–433.
10.
RothhammerVMascanfroniIDBunseL, et al. Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor. Nat Med2016; 22(6): 586–597.
11.
BlewettMMXieJZaroBW, et al. Chemical proteomic map of dimethyl fumarate-sensitive cysteines in primary human T cells. Sci Signal2016; 9(445): rs10.
12.
BollongMJLeeGCoukosJS, et al. A metabolite-derived protein modification integrates glycolysis with KEAP1–NRF2 signalling. Nature2018; 562(7728): 600–604.
13.
WorleyBPowersR. PCA as a practical indicator of OPLS-DA model reliability. Curr Metabolomics2016; 4(2): 97–103.
14.
ArlotSCelisseA. A survey of cross-validation procedures for model selection. Stat Surv2010; 4: 40–79.
15.
LangfelderPHorvathS. WGCNA: An R package for weighted correlation network analysis. BMC Bioinformatics2008; 9: 559.
16.
BhargavaPFitzgeraldKCCalabresiPA, et al. Metabolic alterations in multiple sclerosis and the impact of vitamin D supplementation. JCI Insight2017; 2(19): 95302.
17.
BhargavaPFitzgeraldKCVenkataSLV, et al. Dimethyl fumarate treatment induces lipid metabolism alterations that are linked to immunological changes. Ann Clin Transl Neurol2018; 6: 33–45.
18.
LusczekERLexcenDRWitowskiNE, et al. Urinary metabolic network analysis in trauma, hemorrhagic shock, and resuscitation. Metabolomics2013; 9(1): 223–235.
19.
LynchJPeelingJAutyA, et al. Nuclear magnetic resonance study of cerebrospinal fluid from patients with multiple sclerosis. Can J Neurol Sci1993; 20(3): 194–198.
20.
SimoneILFedericoFTrojanoM, et al. High resolution proton MR spectroscopy of cerebrospinal fluid in MS patients. J Neurol Sci1996; 144(1–2): 182–190.
21.
ReinkeSNBroadhurstDLSykesBD, et al. Metabolomic profiling in multiple sclerosis: Insights into biomarkers and pathogenesis. Mult Scler2014; 20(10): 1396–1400.
22.
KimH-HJeongIHHyunJS, et al. Metabolomic profiling of CSF in multiple sclerosis and neuromyelitis optica spectrum disorder by nuclear magnetic resonance. PLoS ONE2017; 12(7): e0181758.
23.
HermanSÅkerfeldtTSpjuthO, et al. Biochemical differences in cerebrospinal fluid between secondary progressive and relapsing–remitting multiple sclerosis. Cells2019; 8(2): 84.
24.
MehrpourMKyaniATafazzoliM, et al. A metabonomics investigation of multiple sclerosis by nuclear magnetic resonance. Magn Reson Chem2013; 51(2): 102–109.
25.
MoussalliehF-MElbayedKChansonJB, et al. Serum analysis by 1H nuclear magnetic resonance spectroscopy: A new tool for distinguishing neuromyelitis optica from multiple sclerosis. Mult Scler2014; 20(5): 558–565.
26.
VillosladaPAlonsoCAgirrezabalI, et al. Metabolomic signatures associated with disease severity in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm2017; 4(2): e321.
27.
LimCKBilginALovejoyDB, et al. Kynurenine pathway metabolomics predicts and provides mechanistic insight into multiple sclerosis progression. Sci Rep2017; 7: 41473.
28.
LazzarinoGAmoriniAMPetzoldA, et al. Serum compounds of energy metabolism impairment are related to disability, disease course and neuroimaging in multiple sclerosis. Mol Neurobiol2017; 54: 7520–7533.
29.
CoccoEMurgiaFLoreficeL, et al. 1H-NMR analysis provides a metabolomic profile of patients with multiple sclerosis. Neurol Neuroimmunol Neuroinflamm2016; 3(1): e185.
30.
NourbakhshBBhargavaPTremlettH, et al. Altered tryptophan metabolism is associated with pediatric multiple sclerosis risk and course. Ann Clin Transl Neurol2018; 5: 1211–1221.
31.
DickensAMLarkinJRGriffinJL, et al. A type 2 biomarker separates relapsing-remitting from secondary progressive multiple sclerosis. Neurology2014; 83(17): 1492–1499.
32.
BaoQFengJChenL, et al. A robust automatic phase correction method for signal dense spectra. J Magn Reson2013; 234: 82–89.
33.
WangJThingholmLBSkiecevicieneJ, et al. Genome-wide association analysis identifies variation in vitamin D receptor and other host factors influencing the gut microbiota. Nat Genet2016; 48(11): 1396–1406.
34.
BhargavaPSteeleSCassardS, et al. The vitamin D to ameliorate multiple sclerosis (VIDAMS) trial (P3.191). Neurology2014; 82(10Suppl.): P3–P191.
35.
RothhammerVBoruckiDMTjonEC, et al. Microglial control of astrocytes in response to microbial metabolites. Nature2018; 557(7707): 724–728.
36.
BhargavaPMischeLSmithM, et al. Bile acid metabolism is altered in MS and supplementation leads to amelioration of neuroinflammation. Mult. Scler2018; 24: 119–119.
37.
PedersenHKGudmundsdottirVNielsenHB, et al. Human gut microbes impact host serum metabolome and insulin sensitivity. Nature2016; 535(7612): 376–381.
38.
RinschenMMIvanisevicJGieraM, et al. Identification of bioactive metabolites using activity metabolomics. Nat Rev Mol Cell Biol2019; 20(6): 353–367.
